Table 2. List of studies detecting differential expression of miR-126* or miR-126, with their respective directions of change.
| Study type | Study | miR | Sample type | Direction of change (PE sub-type) |
|---|---|---|---|---|
| Screening | [38] | 126* | Placenta | Increase (higher in mPE) |
| Screening | [51] | 126 | Placenta | Increase (sPE) |
| Screening | [46] | 126* | Placenta | Increase (mostly loPE) |
| Screening | [47] | 126 | Placenta | Decrease (sPE) |
| Screening | [48] | 126 | Serum | Decrease (sPE) |
| Screening | [53] | 126,126* | Placenta & Plasma | Increasea |
| Screening | [44] | 126* | Placenta | Decrease (sPE) |
| Candidate | [96] | 126 | Placenta | Decrease |
| Candidate | [97] | 126 | Placenta & EPCsb | Decrease |
aIn this study, miR-126 and -126* were upregulated in both placental and plasma samples with varying levels of expression between sample types and fold change differences between mPE and sPE.
bEPC = Endothelial progenitor cell.